Aquestive Therapeutics ( (AQST) ) has shared an announcement.
Aquestive Therapeutics, Inc. is actively engaging investors with an update on its innovative Adrenaverse™ epinephrine prodrug platform, presenting developments in their Anaphylm™ Sublingual Film and AQST-108 Topical Gel during a virtual investor day. The company aims to navigate the FDA approval process, highlighting potential market opportunities and unique benefits their products could offer to patients. They also address various risks and uncertainties, including market acceptance and potential competition, while underscoring their commitment to overcome regulatory and commercialization challenges.
See more data about AQST stock on TipRanks’ Stock Analysis page.
